Cytochrome P4501A1 polymorphisms in a Caucasian population with porphyria cutanea tarda

Experimental Dermatology

Volumn 12, Issue 6, 2003, Pages 843-848

  Gardlo, K ^a   Selimovic, D ^a   Bolsen, K ^a   Ruzicka, T ^a   Abel, J ^b   Fritsch, C ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Med Inst of Environmental Hygiene   (Germany)

Author keywords

Cytochrome P450; Polymorphism; Porphyria cutanea tarda; Porphyrogens

Indexed keywords

CYTOCHROME P450 1A1; PORPHYRIN DERIVATIVE; UROPORPHYRINOGEN DECARBOXYLASE; CYTOCHROME P450; PORPHYRIN;

ADULT; AGED; ALLELE; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DISEASE CLASSIFICATION; ENZYME ACTIVITY; ENZYME POLYMORPHISM; FAMILIAL DISEASE; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; POLYMERASE CHAIN REACTION; PORPHYRIA CUTANEA TARDA; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCHOOL CHILD; ETHNOLOGY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; METABOLISM; RISK; URINE;

ALLELES; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 ENZYME SYSTEM; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; ODDS RATIO; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PORPHYRIA CUTANEA TARDA; PORPHYRINS; UROPORPHYRINOGEN DECARBOXYLASE;

EID: 0346339866     PISSN: 09066705     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0906-6705.2003.00095.x     Document Type: Article

References (32)

1. Elder G H, Lee G B, Tovey J A. Decreased activity of hepatic uroporphyrin decarboxylase in sporadic porphyria cutanea tarda. N Engl J Med 1978: 299: 274-278.
2. Elder G H, Sheppardd D M, De Salamanca R E, Olmos A. Identification of two forms of porphyria cutanea tarda by measurement of red cell uroporphyrinogen-decarboxylase. Clin Sci 1980: 58: 477-484.
3. DeVerneuil H, Aitken G, Nordmann Y. Familial and sporadic porphyria cutanea tarda: Two different diseases. Human Genet 1978: 44: 145-152.
4. DeVerneuil J, Grandchamp B, Beaumont C, Picat C, Nordman Y. Uroporphyrin decarbxylase structural mutant (Gly281Glu) in a case of porphyria. Science 1986: 234: 732-734.
5. Elder G H. Update on enzyme and molecular defects in porphyria. Photodermatol Photoimmunol Photomed 1998: 14: 66-69.
6. Garey J R, Franklin K F, Brown D A, Harrison L M, Metcalf K M, Kushner J P. Analysis of uroporphyrinogen decarboxylase complementary DNAs in sporadic porphyria cutanea tarda. Gastroenterology 1993: 105: 165-169.
7. Robertson A G, Elder G H, Newcombe R G, De Salamanca R E, Munoz J J. Heterogeneity of familial porphyria cutanea tarda. J Med Genet 1988: 25: 669-676.
8. Hansen J L, Pryor M A, Kennedy J B, Kushner J P. Steady-state levels of uroporphyrinogen decarboxylase mRNA in lymphoblastoid cell lines from patients with familial porphyria cutanea tarda and their relatives. Ann J Hum Genet 1988: 42: 847-853.
9. DeVerneuil J, Beaumont J C, Deybach J C, Nordman Y, Sfar Z, Kastally R. Enzymatic and immunological studies of porphyrinogen decarboxylase in familial porphyria cutanea tarda and hepatoerythropoietic porphyria. Ann J Hum Genet 1984: 36: 613-622.
10. Fritsch C, Bolsen K, Ruzicka T, Goerz G. Congenital erythropoietic porphyria. J Am Acad Dermatol 1997: 36: 594-610.
11. Lim H W. Role of viral infection in porphyria cutanea tarda. Photodermatol Photoimmunol Photomed 1997: 13: 75-77.
12. Moran M J, Fontanellas A, Brudieux E et al. Hepatic uroporphyrinogen decarboxylase activity in porphyria cutanea tarda patients: The influence of virus C infection. Hepatology 1998: 27: 584-589.
13. Herrero C, Vincente A, Bruguera M et al. Is hepatitis C virus infection a trigger of porphyria cutanea tarda? Lancet 1993: 341: 788-789.
14. Carpintero P, DeCastro M, Garcia Monzon C et al. Hepatitis C virus infection detected by viral RNA analysis in porphyria cutanea tarda. J Infect 1997: 34: 61-64.
15. Lamoril J, Andant C, Bogard C et al. Epidemiology of hepatitis C and G in sporadic and familial porphyria cutanea tarda. Hepatology 1998: 27: 848-852.
16. Fritsch C, Lang K, Von Schmiedeberg S et al. Porphyria cutanea tarda. Skin Pharm Appl Skin Physiol 1998: 11: 321-335.
17. Kushner J P, Steinmoller D P, Lee G R. The role of iron in the pathogenesis of porphyria cutanea tarda. II. Inhibition of uroporphyrinogen decarboxylase. J Clin Invest 1975: 56: 661-675.
18. Menon IA, Becker M A, Haberman H F. Role of iron in the phosphotosensitization of uroporphyrin. Clin Chim Acta 1991: 202: 237-242.
19. Goerz G, Barnstorf W, Winnekendonk G et al. Influence of UVA and UVB irradiation on hepatic and cutaneous P450 isoenzymes. Arch Dermatol Res 1996: 289: 46-51.
20. Kawajiri K, Fujii-Kuriyama Y. P450 cancer. Jpn J Cancer Res 1991: 82: 1325-2335.
21. Yager J D. Molecular mechanisms of oestrogen carcinogenesis. Annu Rev Pharmacol Toxicol 1996: 36: 203-232.
22. Christiansen L, Bygum A, Jensen A et al. Association between CYP1A2 polymorphisms and susceptibility to porphyria cutanea tarda. Hum Genet 2000: 107: 612-614.
23. Akthar R A, Smith A G. Chromosomal linkage analysis of porphyria in mice induced by hexachlorbenzene-iron synergism: A model of sporadic porphyria cutanea tarda. Pharmacogenetics 1998: 8: 485-494.
24. Drakoulis N, Cascorbi I, Brockmöller J, Gross C R, Roots I. Polymorphisms in the human CYP1A1 gene as susceptibility factors for lung cancer. Exon-7 mutation (4889 A to G), and a T to C mutation in the 3′-flanking region. Clin Invest 1994: 72: 240-248.
25. Cascorbi I, Brockmöller R, Roots I. A C4887A polymorphism in exon 7 of human CYP1A1: Population frequency, mutation linkages and impact on lung cancer susceptibility. Cancer Res 1996: 56: 4965-4969.
26. Doss M, Schmidt A. Rapid determination of urinary total porphyrins by ion exchange chromatography. Z Klin Chem Klin Biochem 1971: 9: 415-418.
27. Fritsche E, Schuppe H C, Döhr O, Ruzicka T, Gleichmann E, Abel J. Increased frequencies of cytochrome P450 1A1 polymorphisms in infertile men. Andrologia 1998: 30: 125-128.
28. Seubert A, Seubert S. High-performance liquid chromatographic analysis of porphyrins and their isomers with radial compression columns. Anal Biochem 1982: 124: 303-307.
29. Adjarov D G, Elder G H. A simplified method for determination of uroporphyrinogen decarboxylase activity in human blood. Clin Chim Acta 1988: 177: 123-130.
30. Mrozikiewicz P M, Cascorbi I, Brockmöller J, Roots I. CYP1A1 mutations 4887A, 4889G, 5639C and 6235C in the Polish population and their allelic linkage, determined by peptide nucleid acid-mediated PCR clamping. Pharmacogenetics 1997: 7: 303-307.
31. Duppont W D, Plummer W D. Power and sample size calculation: A review and computer program. Controlled Clin Trials 1990: 11: 116-128.
32. Sinclair P R, Gorman N, Dalton T et al. Uroporphyria produced in mice by iron and 5-aminolevulinic acid does not occur in Cyp1A2 (-/-) null mutant mice. Biochem J 1998: 330: 149-153.